Droia Ventures
Tracked across 1 events · 8 articles · First seen Aug 11, 2026 · Last active Aug 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on rare vascular diseases, announced the closing of an oversubscribed $152 million Series B financing and the initiation of its global Phase 3 HEROIC study. The financing was…
Impact: Existing investor, participated in the financing, reinforcing its commitment to Vaderis's development.
Aug 11, 2026 · 8 articles
60
Droia Ventures participated in financing Vaderis TherapeuticsVaderis $152M Series B and...
ERGEN INTELLIGENCE
Track Droia Ventures live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard